Anavex Life Sciences Corp (AVXL)

[hnbadger1]

A repost of Jesse’s post on ST on 8/31/25 for people that upset about what the p2 was intended to accomplish!

MayoMobile 8/31/25, 10:54 PM
SAVXL @mqwlaser
Don and I have collaborated at decent length to come to these conclusions. The 3-71 trial is studying safety in stable schizophrenia patients. The novel mechanism of 3-71 is of such high magnitude (strength via exceedingly high binding) that the company needed to be sure of safety - especially since part A was technically still dose-finding.
EEG biomarkers for schizophrenia are new 2025 technological advances. Some of you will remember the ERP Biomarker Qualification Consortium and Anavex's involvement.
Confirmation of positive, negative, and cognitive electrical biomarkers (EEG) improvement for blinded part B that we've already seen a bit of in part A along with CONSISTENT stabilization in these patients will be key.
PANSS and cognitive improvement in
"secondary outcomes" may only trend in benefit. As mentioned by Don, these patients are already stable, so improvement would likely be low magnitude and might not hit stat sig - which wasn't the intent of trial.
Bullish
BULLISH